

INFLUENZA VACCINES FOR THE WORLD

6-9 October 2015, Sao Rafael Atlantic Hotel, Albufeira, Algarve, Portugal

SECOND CIRCULAR AND PROVISIONAL CONFERENCE PROGRAMME FOR IVW 2015

Influenza Vaccines for the World – IVW 2015 is the fifth international conference and exhibition in this important series of influenza vaccine meetings. The IVW conference series focuses on 'Influenza Vaccination Issues' and is designed to complement the other two major influenza meetings in the conference calendar: *ESWI* and the *Options for Control of Influenza*.

The IVW series is an international forum for world renowned experts in the field of influenza vaccines and related issues (adjuvants/delivery/vaccination strategies) to report on the latest data and trends associated with current and new influenza vaccines/technologies and their availability/delivery/implementation worldwide.

The IVW 2015 Scientific Advisory Panel invites the influenza community worldwide to submit Late-Breaking abstracts for consideration for inclusion in the IVW 2015 Final Oral & Poster Scientific Programmes.

SCIENTIFIC ADVISORY PANEL

Othmar Engelhardt (*NIBSC/HPA, Potters Bar, UK*)

Eric Desauziers (*Sanofi-Pasteur, Lyon, France*)

John Oxford (*hVIVO Ltd., London, UK*)

Albert Osterhaus (*Erasmus University, Rotterdam, The Netherlands*)

Ted Ross (*University of Georgia, Athens, Georgia, USA*)

Yoshihiro Kawaoka (*University of Wisconsin, Madison, Wisconsin, USA*)

Helen Bright (*MedImmune, Liverpool, UK*)

Jonathan Van Tam (*University of Nottingham, UK*)

Rob Lambkin-Williams (*hVIVO Ltd., London, UK*)

Dirk Poelaert (*GSK Vaccines, Wavre, Belgium*)

Ronald Kompier (*FluConsult, Noordwijk, The Netherlands*)

Keiji Fukuda (*WHO, Geneva, Switzerland*)

Manon Cox (*Protein Sciences Corporation, Meriden, Connecticut, USA*)

Emanuele Montomoli (*VisMederi Srl, Siena, Italy*)

Yotam Levin (*NanoPass Technologies Ltd, Rehovot, Israel*)

Manmohan Singh (*Novartis Influenza Vaccines, Holly Springs, North Carolina, USA*)

Anna-Karin Maltais (*Eurocine Vaccines AB, Solna, Sweden*)

Edward Remarque (*BPRC, Rijswijk, The Netherlands*)

CONFERENCE SCOPE

IVW 2015 will address the following important topics:


Surveillance Issues / Burden of Disease · Immunological Issues · Social / Political / Financial Issues Surrounding Influenza Vaccination

Novel Developments · Production / Formulation Issues / Manufacturing Issues · Vaccine Usage / Targeting Strategies

Influenza Vaccines / Adjuvants – Improvement Issues · Pandemic Preparedness Issues / Licensing Issues

CALL FOR LATEBREAKING ORAL AND POSTER ABSTRACTS

Latebreaker abstracts for oral and poster presentation are called for. Please submit your abstract for either oral or poster presentation to John Herriot, IVW 2015 Organizer at jherriot@meetingsmgmt.u-net.com by Wednesday 9th September 2015.



PROVISIONAL CONFERENCE PROGRAMME · TUESDAY 6TH OCTOBER

Morning

Arrival, Registration, Poster and Exhibits Set-Up

Lunch Break & Posters & Exhibits

SESSION 1: OPENING PLENARY SESSION

Moderator: John S. Oxford

(Queen Mary College London / hVIVO Ltd / Oxford Media & Medicine, London, UK)

Welcome to IWV 2015

‘From pneumococcus during the Spanish Influenza to EU universal influenza vaccines: A hundred years journey’

John S. Oxford

(Queen Mary College London / hVIVO Ltd., London, UK)

‘Human genes and Influenza’

Paul Kelham

(Sanger Institute, Cambridge, UK) – To be confirmed

‘Development of high-yield influenza vaccine viruses’

Yoshihiro Kawaoka

(University of Wisconsin, Madison, Wisconsin, USA)

Keynote:

‘Universal influenza vaccines: Designs and developments’

Sarah Gilbert

(University of Oxford, Oxford, UK)

‘Influenza vaccines: Where are we from a public health perspective?’

Speaker to be confirmed

(ECDC, Stockholm, Sweden)

‘Phenotypes, evolution and global public health: Treating the host response to pandemic influenza’

David Fedson

(Independent Consultant, Sergy Haut, France)

Tea Break & Posters & Exhibits

SESSION 2: SPECIAL SESSION

Moderator: To be confirmed

‘An IFPMA survey methodology to assess global influenza vaccine dose distribution: Latest data report’

Bram Palache

(IFPMA: International Federation of Pharmaceutical Manufacturers & Associations, Geneva, Switzerland)

‘Evaluating real-time influenza vaccine effectiveness in Europe’

Speaker to be confirmed

(Epi-Concept, Paris, France)

‘UK experience with LAIV: Pilot data update’

Speaker to be confirmed

(Public Health England, Colindale, London, UK)

‘Immunological analysis for influenza vaccines licensing, corresponding requirements from regulatory agencies and future perspectives’

Emanuele Montomoli and Simona Piccirella

(VisMederi srl, Siena, Italy)

‘EduFluVac project introduction and overview’

Edward Remarque

(BPRC, Rijswijk, The Netherlands)

IWV 2015 Welcome Reception & Posters & Exhibits

PROVISIONAL CONFERENCE PROGRAMME · WEDNESDAY 7TH OCTOBER

SESSION 3: INFLUENZA VACCINES: BURDEN/SURVEILLANCE/POTENCY

Moderator: Ronald Kompier

(FluConsult, Noordwijk, The Netherlands)

‘Potency testing of inactivated influenza vaccines: Overview and update on alternative potency assay for inactivated influenza viruses’

Chung Cheung and Othmar Engelhardt

(NIBSC/HPA, Potters Bar, UK)

‘Seasonal vaccination, burden of disease and the need for quadrivalent seasonal vaccines’

Speaker to be confirmed

(GSK Vaccines R&D, Wavre, Belgium)

‘H7N9 influenza T cell epitopes similar to human sequences are less immunogenic and may induce Treg-mediated tolerance: Implications for vaccine design’

Annie De Groot

(EpiV Inc./University of Rhode Island, Providence, Rhode Island, USA)

‘Identification of the genetic signatures in the hemagglutinin (HA) protein that control the stability of live attenuated influenza vaccines’

Ruben Maeso, Alice Eaton, Zhongying Chen, Helen Bright

(MedImmune UK Ltd, Liverpool, United Kingdom)

‘M2e-specific T Cell-engaging antibodies protect against Influenza A virus infection’

Kenny Roose^{2,3}, Jochen Pendzialek¹, Anouk Smet^{2,3}, Peter Kufer¹, Tobias Raum¹,

Patrick A. Baeuerle¹, Markus Muenz¹, Xavier Saelens^{2,3} and Walter Fiers^{2,3}

(1 Amgen Research (Munich) GmbH, Munich, Germany; 2 VIB, Ghent, Belgium;

3 Ghent University, Ghent, Belgium)

‘Deep sequencing reveals potential antigenic drift variants at low frequency in influenza A-infected humans’

Thomas C. Friedrich, Nicholas W. Florek, Omolayo O. Fatola, Louise H. Moncla,

James P. Mutschler, Jennifer K. Meece, Edward A. Belongia and Jorge M. Dinis

(University of Wisconsin-Madison, Wisconsin, USA)

‘Titer on chip: New analytical tool for influenza vaccine potency determination’

Kathy L. Rowlen

(InDevR, Inc., Boulder, Colorado, USA)

Coffee Break & Posters & Exhibits

SESSION 4: SAFETY, EFFICACY AND IMMUNOGENICITY

Moderator: Rob Lambkin-Williams

(hVIVO Ltd., London, UK)

‘Pandemic influenza A H1N1 vaccines and narcolepsy’

Speaker to be confirmed

‘Safety, efficacy and immunogenicity of Flublok® in the prevention of season influenza in adults’

Manon M.J. Cox, Ruvim Izikson, Penny Post, and Lisa Dunkle
(Protein Sciences Corporation, Meriden, Connecticut, USA)

‘Safety and immunogenicity of an intramuscular quadrivalent Influenza vaccine in children 3 to 8 years of age’

Stephanie Pepin¹, Henryk Szymanski², Ilya Angélica Rochín Kobash³, Sandra María Villagómez Martínez⁴, José Francisco González Zamora⁴, Jerzy Brzostek⁵, Li-Min Huang⁶, Cheng-Hsun Chiu⁶, Po-Yen Chen⁷, Anitta Ahonen⁸, Aino Forstén⁹, Edyta Miszczak-Kowalska¹⁰, Ilkka Seppä¹¹, René Farfán Quiroz¹², Tiina Korhonen¹³, Enrique Rivas¹⁴, Celine Monfredo¹, Yaneé Hutagalung¹⁵ and Timo Vesikari¹⁶
(1 Sanofi Pasteur, Marcy l'Etoile, France; 2 St. Hedvig of Silesia Hospital, Poland; 3 Centro de Investigación Clínica del Pacífico, México; 4 Instituto Nacional de Pediatría, México; 5 Zespół Opieki Zdrowotnej, Poland; 6 National Taiwan University Hospital, Taiwan R.O.C.; 7 Chang Gung Children's Hospital, Taiwan R.O.C.; 8 Taichung Veterans General Hospital, Taiwan R.O.C.; 9 Helsinki South Vaccine Research Clinic, Finland; 10 Pori and Espoo Vaccine Research Clinics, Finland; 11 Independent physician, Poland; 12 Turku Vaccine Research Clinic, Finland; 13 Hospital Infantil de Tlaxcala, México; 14 Tampere Vaccine Research Clinic, Finland; 15 Sanofi Pasteur, Mexico; 16 Sanofi Pasteur, Singapore; 16 University of Tampere Medical School, Finland)

‘Vaccine efficacy of Flublok® quadrivalent vs. IIV4 in Adults ≥50 years of age’

Manon M.J. Cox, Ruvim Izikson and Lisa M. Dunkle
(Protein Sciences Corporation, Meriden, Connecticut, USA)

‘Drugs influencing immune response and patient outcomes following influenza vaccination: A systematic review’

Subhadra Rajanaidu, Puja Myles and Jonathan Nguyen Van Tam
(University of Nottingham, Nottingham, UK)

‘Broad cross-protective HAI responses induced by influenza consensus DNA vaccine’

Jian Yan, Matthew Morrow, Jaemi Chu, Janess Mendoza, Trina Racine, Amir S. Khan, Kate Broderick, Gary Kobinger, David B. Weiner and Niranjana Y. Sardesai
(INOVO Inc., Plymouth Meeting, Pennsylvania, USA)

‘Automated imaging and standardized interpretation of hemagglutination assays’

Kathy L. Rowlen
(InDevR Inc., Boulder, Colorado, USA)

Lunch Break & Posters & Exhibits

SESSION 5: INFLUENZA VACCINES/VACCINATION DEVELOPMENT

Moderator: Ted Ross
(University of Georgia, Athens, Georgia, USA)

‘Bio-modelling of immune responses to influenza vaccination’

Behazine Combadiere
(UPMC/INSERM, Cimi- Paris, Paris, France)

‘Vaccine platform in response to emerging infectious diseases: A/H7N9 flu and Ebola Zaire nanoparticles’

Gale Smith (Novavax Inc., Gaithersburg, Maryland, USA)

‘Development of an inactivated nasal influenza vaccine’

Anna-Karin Maltais
(Eurocine Vaccines AB, Solna, Sweden)

‘M2SR: A single replication next generation live influenza vaccine’

P. Bilsel, Y. Hatta, S. Sarawar, T.M. Ross, C. Crevar, A. Kelvin, D. Kelvin, D. Banner, S. Watanabe, G. Neumann and Y. Kawaoka
(Flugen Inc., Madison, Wisconsin, USA)

‘Recombinant multi-subtype VLPs as broadly protective influenza vaccines’

Peter Pushko
(Medigen, Inc., Frederick, Maryland, USA)

‘Broad cross-protective HAI responses induced by influenza consensus DNA vaccine’

Jian Yan, Matthew Morrow, Jaemi Chu, Janess Mendoza, Trina Racine, Amir S. Khan, Kate Broderick, Gary Kobinger, David B. Weiner and Niranjana Y. Sardesai
(INOVO Inc., Plymouth Meeting, Pennsylvania, USA)

‘The large-scale production of an artificial influenza virus-like particle vaccine in silkworm pupae’

Kuniaki Nerome¹, Shigeo Sugita², Kazumichi Kuroda³, Sayaka Matsuda¹, Kei Majima⁴, Kazunori Kawasaki⁵ and Reiko Nerome¹
(1 The Institute of Biological Resources, Nakayama, Japan; 2 Equine Research Institute, Tokami-cho, Japan; 3 Division of Microbiology, Nihon University School of Medicine, Oyaguchi-kamicho, Japan; 4 Baculotechnologies Co., Ltd., Hayashi-cho, Japan; 5 National Institute of Advanced Science and Technology, Midorigaoka, Japan)

Tea Break & Posters & Exhibits

SESSION 6: UNIVERSAL INFLUENZA VACCINES

Moderator: Manon Cox
(Protein Sciences Corporation, Meriden, Connecticut, USA)

Keynote: ‘Universal influenza vaccine challenges and hurdles’

Helen Bright (AstraZeneca biologics, Liverpool, UK)

‘Developing universal and intra-seasonal flu vaccines: Why the human viral challenge model is so important’

Rob Lambkin-Williams (hVIVO Ltd., London, UK)

‘Design and characterization of a universal H1N1 COBRA HA vaccine’

Ted M. Ross, Donald M. Carter, Christopher A. Darby, Bradford C. LeFoley, Cory J. Crevar, Timothy Alefantis, Stephen Anderson, Tod Strugnell, Guadalupe Cortes, Thorsten U. Vogel and Harold Kleanthous
(University of Georgia, Athens, Georgia, USA)

‘Infection-permissive immunity provided by NA- and universal M2e-based vaccines protects against influenza A virus challenge and allows the induction of heterosubtypic immunity during subsequent infections’

Michael Schotsaert, Tine Ysenbaert, Anouk Smet, Bert Schepens, Walter Fiers and Xavier Saelens (Ghent University, Ghent, Belgium; Icahn School of Medicine at Mount Sinai, New York, USA)

‘The development of a universal live-attenuated H1N1 vaccine strain’

Ke Xu and Xianqiang Ping (Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China)

CALL FOR LATEBREAKING ORAL AND POSTER ABSTRACTS

Latebreaker abstracts for oral and poster presentation are called for. Please submit your abstract for either oral or poster presentation to John Herriot, IVW 2015 Organizer at jherriot@meetingsmgmt.u-net.com by Wednesday 9th September 2015.

SESSION 7: ADJUVANTS & FORMULATION & DELIVERY

Moderator: Manmohan Singh

(Novartis Influenza Vaccines, Holly Springs, North Carolina, USA)

'Adjuvants in pandemic and seasonal influenza vaccines'

Timo Vesikari

(University of Tampere, Tampere, Finland)

'History of emulsion based adjuvants and their use in influenza vaccination'

Manmohan Singh

(Novartis Influenza Vaccines, Holly Springs, North Carolina, USA)

'Safety and tolerability evaluation of the use of Montanide ISATM 51 as vaccine adjuvant: A systematic review'

Eva van Doorn¹, Heng Liu¹, Anke Huckriede² and Elko Hak¹

(1 Unit of PharmacoEpidemiology and PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, The Netherlands;
2 Department of Medical Microbiology, University of Groningen, University Medical Center of Groningen, The Netherlands)

'Dry powder vaccines as a stable, effective and convenient alternative to parenteral influenza vaccines'

Anke Huckriede, Harshad P. Patil, Senthil Murugappan, Tjarko Meijerhof, Hendrik W. Frijlink and Wouter L.J. Hinrichs

(University Medical Center Groningen, Groningen, The Netherlands)

'Oral tablet delivery induces systemic and mucosal antibody responses to influenza in humans'

Sean Tucker

(VAXART Inc., South San Francisco, California, USA)

'Exposition of influenza A antigens on the surface of recombinant *Bacillus subtilis* endospores'

Bogus Szewczyk, Paulina Pranszke, Tomasz Lega and Dawid Nidzworski
(University of Gdansk and Medical University of Gdansk, Gdansk, Poland)

Coffee Break & Posters & Exhibits

SESSION 8: SPECIAL SESSION

'Advances in the clinical development of plant-made influenza VLP vaccines'

Moderator: Marc-Andre D'Aoust

(Medicago Inc., Sainte-Foy-Sillery-Cap-Rouge, Quebec, Canada)

'Plant-made VLP vaccines for influenza: The first 15 minutes'

Brian J. Ward

(McGill University, Montreal, Quebec, Canada)

'Plant-made influenza VLP vaccines and the aging immune system'

Connie Michele Krawczyk

(McGill University, Montreal, Quebec, Canada)

'Plant-made influenza VLP vaccines in the elderly: Clinical trial update'

Nathalie Landry

(Medicago Inc., Sainte-Foy-Sillery-Cap-Rouge, Quebec, Canada)

Lunch Break & Posters & Exhibits

SESSION 9: INFLUENZA VACCINES

Moderator: To be confirmed

'The development of pandemic live attenuated influenza vaccines'

Helen Bright

(AstraZeneca Biologics, Liverpool, UK)

'Efficacy and effectiveness of 2009 pandemic influenza A(H1N1) pdm09 vaccines: A systemic review and meta-analysis'

Louise E. Lansbury, Sherie Smith, Charles R. Beck

and Jonathan S. Huyen-Van-Tam

(University of Nottingham, Nottingham, UK)

'Pandemic swine-origin H1N1 influenza virus replicates to higher levels and induces more fever and acute inflammatory cytokines in cynomolgus versus rhesus monkeys and can replicate in common marmosets'

Petra Mooij, Gerrit Koopman, Daniella M. Mortier,

Melanie van Heteren, Zahra Fagrouch, Rudy de Laat,

Edmond J. Remarque, Ivanela Kondova, Ernst J. Verschoor

and Willy M.J.M. Bogers

(Biomedical Primate Research Centre, Rijswijk, The Netherlands)

'Characterization and development of replication competent DeINs1 live attenuated influenza vaccine for cross protection of heterosubtype influenza virus infection'

Honglin Chen, Min Zheng, Pui Wang, Wenjun Song, Siu-Ying Lau,

Bobo Mok, Siwen Liu, Xiaofeng Huang and Kwok-Yung Yuen

(The University of Hong Kong, Hong Kong)

'The experience of A/H5N1 vaccine immunization program in Taiwan and an investigation on vaccine adverse events'

Chin-Hui Yang, Yun-Jui Shih, Li-Ching Hsu, Yi-Chien Chih

and Shu-Mei Chou

(Center for Disease Control, Taipei, Taiwan, Republic of China)

Tea Break & Leisure Time For IVW 2015 Delegates

CALL FOR LATEBREAKING ORAL AND POSTER ABSTRACTS

Latebreaker abstracts for oral and poster presentation are called for. Please submit your abstract for either oral or poster presentation to John Herriot, IVW 2015 Organizer at jherriot@meetingsmgmt.u-net.com by Wednesday 9th September 2015.

SESSION 10: SKIN VACCINATION

Moderator: Nathalie Garcon (*BIOASTER, Lyon, France*)

'From muscles to skin:

More variables to consider when vaccinating'

Nathalie Garcon

(*BIOASTER, Lyon, France*)

'Enhancing immune responses to influenza vaccines in high risk groups by skin vaccination'

Dimitrios G. Koutsonanos^{1,2}, E. Stein Esser¹, Sean R. McMaster¹, Priya Kalluri³, Jeong-Woo Lee³, Mark R. Prausnitz³, Ioanna Skountzou^{1,2}, Timothy L. Denning⁴, Jacob E. Kohlmeier^{1,2} and Richard W. Compans^{1,2}
(*1 Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia; 2 Emory-UGA Center of Excellence in Influenza Research and Surveillance, Emory University, School of Medicine, Atlanta, Georgia; 3 School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia; 4 Institute of Biomedical Sciences, Center for Inflammation, Immunity and Infection, Georgia State University, Atlanta, Georgia*)

'Assessing the economic and epidemiological impacts of a microneedle patch influenza vaccine'

Mercy Mvundura², Bruce Y. Lee¹, Sarah M. Bartsch¹, Courtney Jarrahan², Kristina M. Zapf¹, Kathleen Marinan¹, Angela R. Wateska¹, Bill Snyder², Savitha Swaminathan², Erica Jacoby², James J. Norman³, Mark R. Prausnitz³ and Darin Zehrung²
(*1 Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; 2 PATH, Seattle, Washington, USA; 3 Georgia Institute of Technology, Atlanta, Georgia, USA*)

'Influenza microneedle vaccination platform enhances the protective immune responses against flu infection in pregnancy and increases longevity of passive immunity in offspring'

Joanna A. Pulit-Penaloza¹, E. Stein Esser¹, Haripriya Kaluri², Elena V. Vassilieva¹, Devin McAlister², Mark R. Prausnitz², Richard W. Compans¹ and Ioanna Skountzou¹
(*1 Emory University School of Medicine, Atlanta, Georgia, USA and 2 Georgia Institute of Technology, Atlanta, Georgia, USA*)

Coffee Break & Posters & Exhibits

SESSION 11: SPECIAL SESSION – ID DELIVERY OF INFLUENZA VACCINES

Moderator: Yotam Levin (*NanoPass Technologies, Nes Ziona, Israel*)

'MicronJet600®: A novel microneedle device for ID delivery of vaccines – exploring dose-sparing, improved immunogenicity and beyond'

Yotam Levin and Efrat Kochba

(*NanoPass Technologies, Nes Ziona, Israel*)

'Title to be confirmed'

Pierre VanDamme

(*University of Antwerp, Antwerp, Belgium*)

'Title to be confirmed'

Ivan Hung

(*Hong Kong University Queen Mary Hospital, Hong Kong*)

Lunch Break & Posters & Exhibits

SESSION 12: CLOSING SESSION – INFLUENZA VIRUS STRAINS

Moderator: John S. Oxford

(*Queen Mary College London/hVIVO Ltd., London, UK*)

'Emergence of new variant influenza strains and lessons from the past'

Douglas Fleming

(*RCGP Research and Surveillance Centre, Birmingham, UK*)

'Avian Flu Viruses?'

Ab Osterhaus

(*Erasmus University, Rotterdam, The Netherlands*)

'IVW 2015 Overview and Summary Conclusions'

John S. Oxford

(*Queen Mary College London/hVIVO Ltd., London, UK*)

* This provisional programme is correct at the time of printing. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the final conference programme. A final programme with timings will be available in September 2015.

CALL FOR LATEBREAKING ORAL AND POSTER ABSTRACTS

Latebreaker abstracts for oral and poster presentation are called for. Please submit your abstract for either oral or poster presentation to John Herriot, IVW 2015 Organizer at jherriot@meetingsmgmt.u-net.com by Wednesday 9th September 2015.

'Polyvalent influenza: A DNA vaccine for pigs using needle-free intradermal delivery'

Marie Borggren *et al.*

(Statens Serum Institut, Copenhagen, Denmark)

'Evaluating the stockpile and usage strategy of vaccines and antiviral drugs during seasonal and pandemic influenza'

Chia-Kun *et al.*

(Centers for Disease Control, Taipei, Taiwan, Republic of China)

'Design of randomized, double-blind, controlled, multi-center phase IIb trials as part of the EU-funded UNISEC project to assess the safety and immunogenicity of cross-seasonal universal influenza vaccines with or without pandemic influenza vaccine in healthy adults'

H Liu *et al.*

(University of Groningen, Groningen, The Netherlands)

'Mono- and trivalent immunoadjuvant influenza vaccines immunogenicity and safety in pregnant women'


M.P. Kostinov¹, A.P. Cherdantzev² and N.I. Briko³

(1 NIIVS/ I.I. Mechnikov, Moscow, Russia; 2 FSBEI HPO/Ulyanovsk State University, Ulyanovsk, Russia; 3 FSBEI HPO/I.M. Sechenov First Moscow State Medical University, Moscow, Russia)

'The morbidity and vaccination status of influenza in the Russian Federation'

N.I. Briko and T.S. Saltykova

(I.M. Sechenov First Moscow State Medical University, Moscow, Russia)



CALL FOR LATEBREAKING ORAL AND POSTER ABSTRACTS

Latebreaker abstracts for oral and poster presentation are called for. Please submit your abstract for either oral or poster presentation to John Herriot, IVW 2015 Organizer at jherriot@meetingsmgmt.u-net.com by Wednesday 9th September 2015.

REGISTRATION

Delegates should register for IVW 2015 by completing the form provided on the back page of this brochure. The completed Conference Registration Form plus payment (payment in £ Pounds Sterling) should be sent to the IVW 2015 Conference Manager – Caroline Sumner at Meetings Management. The IVW 2015 Conference Registration Desk will be open from 8.30am on Tuesday 6th October 2015.

Delegates can pre-register securely online at:

www.influenzavaccineconference.com

VENUE & ACCOMMODATION

The venue for IVW 2015 is the SAO RAFAEL ATLANTIC HOTEL, which is also the venue for the IVW 2015 conference.

Details on how to book a room at the Sao Rafael Atlantic Hotel, where rooms are available, are listed on the conference website pages under 'ACCOMMODATION' – please use the booking form provided on the website to book accommodation.

PUBLICATION

A USB Memory Device containing final programme and abstracts of all presentations, oral and poster, will be distributed to delegates when they register at the conference.

EXHIBITION

Exhibition space is available at the meeting. Exhibitors can showcase their products or services by reserving a table top exhibit. The exhibit area will be located where all refreshments breaks will be taken to ensure maximum traffic of conference delegates. Exhibits booking fees start at £4995 for Table Top Exhibits. If you require a larger exhibit space then please contact John Herriot at Meetings Management (jherriot@meetingsmgmt.u-net.com).

PLEASE NOTE: If you wish to have additional representatives on your table top exhibit there will be an additional charge for catering levied per head. Please contact the Conference Manager for this additional price.

Please make your bookings and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Table Top Exhibition facilities at IVW 2015 should be directed to John Herriot at Meetings Management (Email: jherriot@meetingsmgmt.u-net.com).

DELEGATE PACK INSERT SERVICE

Company literature/brochures/conference brochures may be distributed to delegates as part of the documentation issued on arrival/registration. One insertion in the IVW 2015 delegate pack is priced at £745. Please make your

booking and payment using the relevant section on the Delegates Registration Form on the back page of this brochure. All general enquiries regarding Delegate Pack Insertion services at IVW 2015 should be directed to John Herriot at Meetings Management (jherriot@meetingsmgmt.u-net.com).

PLEASE NOTE: Literature for distribution to IVW 2015 delegates is subject to approval by the conference organizers.

INSURANCE & CANCELLATION

The organizers cannot be held responsible for any personal accident or damage to their private property of participants at IVW 2015. The organizers strongly urge participants to ensure they have adequate travel and personal insurance cover before they depart for the conference. The organizers cannot be held liable for any costs incurred should the conference be cancelled for any reason. Maximum notice of cancellation will be given by the organizers to all pre-registered delegates.

PROGRAMME

The IVW 2015 Scientific Advisory Panel and the IVW 2015 Conference Organizers reserve the right to alter any part of the published conference programme if this is necessitated by any circumstances outside their control. All efforts will be made to keep any such changes to a minimum. The programme published in the brochure was correct at the time of going to press.

CANNOT ATTEND?

If you and your colleagues are unable to attend the conference, the conference materials (abstracts, speaker handouts, late abstracts, attendee list, pack materials and literature) are available for purchase. While not intended as a substitute for actual attendance, these materials would at least provide a documentary record of the event and allow you to keep you or your organization's library up to date. The cost of providing this non-attendee package is £595 (including postage and packing). To order this package from Meetings Management please use the relevant section in the Delegates Registration Form on the back page of this brochure.

ANY QUESTIONS?

For further information and assistance, please contact: Caroline Sumner IVW 2015 Conference Manager:

IVW 2015 Conference Secretariat, Meetings Management

The Old Dairy Tower, Peper Harow Park, Godalming
Surrey, United Kingdom.

Telephone: +44 (0)1483 427770

Fax: +44 (0)1483 428516

E-mail: csumner@meetingsmgmt.u-net.com

CALL FOR LATEBREAKING ORAL AND POSTER ABSTRACTS

Latebreaker abstracts for oral and poster presentation are called for. Please submit your abstract for either oral or poster presentation to John Herriot, IVW 2015 Organizer at jherriot@meetingsmgmt.u-net.com by Wednesday 9th September 2015.

Please tick appropriate boxes and write clearly in BLOCK CAPITALS or type.

Surname First Name Title
 Organization Address
 Postcode
 Country Telephone Fax
 E-mail (plain type or print):
 If you are an EC business please state your VAT registration number:
 Disabled (please state any special needs): Special diet (please state requirements):

REGISTRATION FEES

Speaker/Delegate Registration Fees:

(Please tick appropriate section)

(NOTE THAT FEES ARE IN UK £ STERLING)

FORMS NOT DULY & FULLY COMPLETED WILL NOT BE VALID

Amount Due (£ Sterling)

☐ Early-Bird Speaker Registration (submitted oral/poster papers) (Payment must be received before Friday 31st July 2015)	£795.00	£.....
☐ Full-Rate Speaker Registration (submitted oral/poster papers) (Payment received after Friday 31st July 2015)	£895.00	£.....
☐ Early-Bird 4 Days Conference Registration (Payment must be received before Friday 31st July 2015)	£1195.00	£.....
☐ Full-Rate 4 Days Conference Registration (Payment received after Friday 31st July 2015)	£1395.00	£.....
☐ Student Registration (price on application)		
☐ Table Top Exhibit (3 metres x 2 metres)	£4995.00	£.....
☐ Delegate Pack Insert (per insert)	£745.00	£.....
☐ Set(s) of IVW 2015 materials (for those unable to attend)	£595.00 (per set)	£.....

Total Amount Payable

£.....

Registration fees include admission to all conference sessions, morning and afternoon refreshments, lunches on the 6th, 7th, 8th and 9th of October 2015 and receptions (where applicable).

PAYMENT

- ☐ I enclose a cheque for £..... made payable to **Meetings Management**. (Delegates registering from outside the UK must ensure that cheques are drawn on a London Bank. Please quote **IVW 2015** on the reverse of the cheque.)
- ☐ I have made a payment by bank transfer (quoting **IVW 2015** on the transfer documentation) to Barclays Bank, Barclays Business Centre, Guildford Branch, PO Box 33, Guildford, Surrey GU1 3AN, UK:
- UK Pounds Sterling Account: Meetings Management 0040614335,
 IBAN GB02BARC20353540614335 SWIFTBIC BARCGB22
- US Dollar Account: Meetings Management 53209211,
 IBAN GB77BARC20353553209211 SWIFTBIC BARCGB22
- Euro Account: Meetings Management 59179600,
 IBAN GB91BARC20353559179600 SWIFTBIC BARCGB22

All transfer charges must be paid by the sender. Delegates paying by this method are requested to send the Conference Manager a copy of the bank transfer. **Payments made by bank transfer must have £15.00 added to the total. PLEASE NOTE THAT IT WILL NOT BE POSSIBLE TO PAY REGISTRATION FEES BY BANK TRANSFER AFTER FRIDAY 4TH SEPTEMBER 2015. LATE PAYMENT AFTER FRIDAY 4TH SEPTEMBER 2015 MUST BE MADE BY CREDIT CARD (VISA/MASTERCARD/AMEX).**

- ☐ I would like to pay £..... by credit card (VISA/MasterCard/American Express only accepted).
- Card no. ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ 3 Digit Security Code (AMEX: 4 Digits)
- Expiry Date Registered Card Address

Please remember that any remittance sent but not received by the time of the conference must be paid again at the Registration desk: we will refund you after the conference. Cancellations received before Friday 28th August 2015 will be refunded in full less an administrative charge of £250 per person. Refunds will not be possible if a cancellation is received after Friday 28th August 2015. Substitutions can be made at any time prior to the conference. Please inform the Conference Manager of any changes. We strongly advise that delegates purchase travel insurance to cover any unforeseen circumstances and protect against loss of hotel deposits and registration fees.

VAT No. 591 617618

Signature Date

PLEASE RETURN THIS FORM TO:

IVW 2015 CONFERENCE SECRETARIAT, MEETINGS MANAGEMENT

The Old Dairy Tower, Peper Harow Park, Godalming, Surrey GU8 6BD, United Kingdom

Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516 E-mail: csumner@meetingsmgmt.u-net.com